← Leaderboards
Victor Shifrin
Immunochem Therapeutics, Llc
$2,797,867
Attributed
$5,836,425
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,836,425 · 4
By mechanism
R44$5,836,425 · 4
Top collaborators
- Jennifer A Kearney4 shared
- D. Martin Watterson2 shared
- Vinai Gondi1 shared
- Haichen Wang1 shared
- Manfred Windisch1 shared
Most similar at Immunochem Therapeutics, Llc
Same institution · by research overlap
- Haichen Wang$249,182
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposPharmaceutical PreparationsSmall MoleculeInflammationSafetyNeuroinflammationPharmacodynamicsCytokinePreparationClinical TrialsNeurogliaImpaired CognitionFutureAnimal ModelNervous System TraumaFunctional DisorderFundingExhibitsDisease ProgressionAttenuatedBrainDrug KineticsDoseProduction
Grant awards (8)
Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk$1,209,751
R44 · FY2025 · AG · contact PI
Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk$50,000
R44 · FY2025 · AG · contact PI
Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk$1,248,699
R44 · FY2024 · AG · contact PI
Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction$722,072
R44 · FY2022 · CA · contact PI
Novel anti-neuroinflammatory drug for aneurysmal subarachnoid hemorrhage (aSAH)$498,363
R44 · FY2022 · NS · contact PI
Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk$450,367
R44 · FY2021 · AG · contact PI
First-in-human study of MW151, a novel drug targeting neuroinflammation$1,157,853
R44 · FY2019 · AG · contact PI
First-in-human study of MW151, a novel drug targeting neuroinflammation$499,320
R44 · FY2018 · AG · contact PI